Skip to content

Effect of Extended Cannabis Abstinence on PTSD Symptoms

PTSD | Cannabis Use | Cognitive Symptom | Comorbidities and Coexisting Conditions

This will be a 12-week randomized trial. Outpatients and patients from the Mood and Anxiety program at the Centre for Addiction and Mental Health (CAMH) with a current diagnosis of post-traumatic stressed disorder (PTSD) and cannabis-use disorder (CUD) will be randomized to receive individual motivational interviewing therapy and contingency management (n = 12) or individual motivational interviewing therapy alone (control group, n = 12) after enrolment.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 to 55

Critères de participation

Inclusion Criteria:

1. Subjects aged between 18 and 55 years (from both sexes \[or genders\]);
2. Diagnosed with CUD (moderate or severe) according to the Structured Clinical Interview for DSM-IV (SCID) (mode of cannabis consumption can be inhalation or ingestion);
3. Diagnosis of current (past 30 days) PTSD, using the CAPS-5 on screening;
4. On antidepressant medication(s) for at least 1 month (to ensure safety and homogeneity as PTSD treatment of our population);
5. Be able to provide written informed consent; and
6. Be able to communicate in English.

Exclusion Criteria:

1. diagnosed with a severe or unstable medical illness that precludes safe participation in the study as per the study physician;
2. diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder or current acute psychosis or mania based on DSM-5 criteria;
3. current suicidality risk as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS) with concurrence after the study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes" 34; and
4. have pain interfering with normal function as reported by the 12-Item Short Form Survey (SF-12) (moderate or higher interference).

Lieu de l'étude

Centre for Addiction and Mental Health
Centre for Addiction and Mental Health
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Ahmed Hassan, MD, MPH

[email protected]
416-535-8501
Backup Contact

Abigail Amartey, MPH

[email protected]
416-535-8501
Étude parrainée par
Centre for Addiction and Mental Health
Participants recherchés
Plus d'informations
ID de l'étude: NCT05162651